[1] de Almeida LLC, Fernandes SP, de Oliveira GD, et al. Harnessing actinobacteria secondary metabolites for tuberculosis drug discovery: historical trends, current status and future outlooks. Nat Prod Bioprospect. 2025;15:52. [2] Dong M, Pfeiffer B, Altmann KH. Recent developments in natural product-based drug discovery for tuberculosis. Drug Discov Today. 2017;22(3):585-91. [3] Zumla A, George A, Sharma V, Herbert RH. Baroness Masham of, I.; Oxley, A.; Oliver, M. The WHO 2014 global tuberculosis report-further to go. Lancet Glob Health. 2015; 3: e10-12. [4] Janin YL. Antituberculosis drugs: ten years of research. Bioorg Med Chem. 2007;15:2479-513. [5] Grzelak EM, Hwang C, Cai G, Nam JW, Choules MP, Gao W, et al. Bioautography with TLC-MS/NMR for rapid discovery of anti-tuberculosis lead compounds from natural sources. ACS Infect Dis. 2016;2:294-301. [6] Hussain A, Hassan QP, Shouche YS. New approaches for antituberculosis leads from Actinobacteria. Drug Discov Today. 2020;25:2335-42. [7] Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994;263:227-30. [8] Vilcheze C, Wang F, Arai M, Hazbon MH, Colangeli R, Kremer L, et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med. 2006;12:1027-9. [9] Maeda K, Kosaka H, Okami Y, Umezawa H. A new antibiotic, pyridomycin. J Antibiot. 1953;6:140. [10] Shomura T, Amano S, Yoshida J, Kojima M. Dactylosporangium fulvum sp. nov. Int J Syst Evol Microbiol. 1986;36:166-9. [11] Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet S, Mukherjee R, et al. Towards a new tuberculosis drug: pyridomycin-nature's isoniazid. EMBO Mol Med. 2012;4:1032-42. [12] Vilcheze C, Jacobs WR, Jr. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: Genes, mutations, and causalities. Microbiol Spectr. 2014; 2: MGM2-0014-2013. [13] Rozman K, Sosic I, Fernandez R, Young RJ, Mendoza A, Gobec S, et al. A new ‘golden age' for the antitubercular target InhA. Drug Discov Today. 2017;22:492-502. [14] Wright GD. Back to the future: a new ‘old' lead for tuberculosis. EMBO Mol Med. 2012;4:1029-31. [15] Luo Y, Cobb RE, Zhao H. Recent advances in natural product discovery. Curr Opin Biotechnol. 2014;30:230-7. [16] Wang M, Carver JJ, Phelan VV, Sanchez LM, Garg N, Peng Y, et al. Sharing and community curation of mass spectrometry data with global natural products social molecular networking. Nat Biotechnol. 2016;34:828-37. [17] Forner D, Berrue F, Correa H, Duncan K, Kerr RG. Chemical dereplication of marine actinomycetes by liquid chromatography-high resolution mass spectrometry profiling and statistical analysis. Anal Chim Acta. 2013;805:70-9. [18] Yang JY, Sanchez LM, Rath CM, Liu X, Boudreau PD, Bruns N, et al. Molecular networking as a dereplication strategy. J Nat Prod. 2013;76:1686-99. [19] Lee B, Son S, Lee JK, Jang M, Heo KT, Ko SK, et al. Isolation of new streptimidone derivatives, glutarimide antibiotics from Streptomyces sp. W3002 using LC-MS-guided screening. J Antibiot. 2020;73:184-8. [20] Hoang C, Uritboonthai W, Hoang L, Billings EM, Aisporna A, Nia FA, et al. Tandem mass spectrometry across platforms. Anal Chem. 2024;96:5478-88. [21] Bocker S. Searching molecular structure databases using tandem MS data: are we there yet? Curr Opin Chem Biol. 2017;36:1-6. [22] Clark TN, Houriet J, Vidar WS, Kellogg JJ, Todd DA, Cech NB, et al. Interlaboratory comparison of untargeted mass spectrometry data uncovers underlying causes for variability. J Nat Prod. 2021;84:824-35. [23] Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, et al. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 2009;5:e1000645. [24] Hartkoorn RC, Pojer F, Read JA, Gingell H, Neres J, Horlacher OP, et al. Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA. Nat Chem Biol. 2014;10:96-8. [25] Huang T, Wang Y, Yin J, Du Y, Tao M, Xu, et al. Identification and characterization of the pyridomycin biosynthetic gene cluster of Streptomyces pyridomyceticus NRRL B-2517. J Biol Chem. 2011;286:20648-57. [26] Kienle M, Eisenring P, Stoessel B, Horlacher OP, Hasler S, van Colen G, et al. Synthesis and structure-activity relationship studies of C2-modified analogs of the antimycobacterial natural product pyridomycin. J Med Chem. 2020;63:1105-31. [27] Huang T, Zhou Z, Wei M, Chen L, Xiao Z, Deng Z, et al. Characterization of pyridomycin B reveals the formation of functional groups in antimycobacterial pyridomycin. Appl Environ Microbiol. 2022;88:e0203521. [28] Huang T, Li L, Brock NL, Deng Z, Lin S. Functional characterization of PyrG, an unusual nonribosomal peptide synthetase module from the pyridomycin biosynthetic pathway. ChemBioChem. 2016;17:1421-5. [29] Hartkoorn RC, Pojer F, Read JA, Gingell H, Neres J, Horlacher OP, et al. Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA. Nat Chem Biol. 2014;10(2):96-8. [30] Lamers C. Overcoming the shortcomings of peptide-based therapeutics. Future Drug Discov. 2022;4:FDD75. [31] da Silva RR, Wang M, Nothias LF, van der Hooft JJ, Caraballo-Rodriguez AM, Fox E, et al. Propagating annotations of molecular networks using in silico fragmentation. PLoS Comput Biol. 2018;14:e1006089. [32] Ernst M, Kang KB, Caraballo-Rodriguez AM, Nothias LF, Wandy J, Chen C, et al. MolNetEnhancer: enhanced molecular networks by integrating metabolome mining and annotation tools. Metabolites. 2019;9:144. [33] Nothias LF, Petras D, Schmid R, Duhrkop K, Rainer J, Sarvepalli A, et al. Feature-based molecular networking in the GNPS analysis environment. Nat Methods. 2020;17:905-8. [34] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498-504. |